Preferred Label : Ribociclib/Letrozole;
NCIt synonyms : Ribociclib Letrozole; Ribociclib and Letrozole Co-pack; Ribociclib Plus Letrozole; Ribociclib-Letrozole Regimen; Ribociclib-Letrozole; Kisqali Femara Co-pack;
NCIt definition : An orally available co-packaged agent combination of ribociclib, a cyclin-dependent
kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole,
a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Ribociclib
specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation.
Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby
arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting
cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which
may result in growth inhibition of estrogen-dependent cancer cells.;
Drug name : Kisqali/Femara; Kisqali and Femara Co-pack;
NCI Metathesaurus CUI : CL759918;
Origin ID : C154675;
UMLS CUI : C4477758;
Semantic type(s)
- concept_is_in_subset
- has_target
